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RESEARCH ARTICLE

4β-Hydroxycholesterol is a prolipogenic factor that
promotes SREBP1c expression and activity through the
liver X receptor
Ofer Moldavski1,2,3, Peter-James H. Zushin4, Charles A. Berdan4, Robert J. Van Eijkeren1,2,
Xuntian Jiang5 , Mingxing Qian6, Daniel S. Ory5, Douglas F. Covey6, Daniel K. Nomura4, Andreas Stahl4,
Ethan J. Weiss3, and Roberto Zoncu1,2,*
1

Department of Molecular and Cell Biology and 2The Paul F. Glenn Center for Aging Research, University of California,
Berkeley, Berkeley, CA, USA; 3Cardiovascular Research Institute, UCSF, San Francisco, CA, USA; 4Department of
Nutritional Sciences and Toxicology, University of California at Berkeley, Berkeley, CA, USA; and 5Diabetic Cardiovascular
Disease Center and 6Department of Developmental Biology, Washington University School of Medicine, St Louis, MO, USA

Abstract Oxysterols are oxidized derivatives of
cholesterol that play regulatory roles in lipid
biosynthesis and homeostasis. How oxysterol
signaling coordinates different lipid classes such as
sterols and triglycerides remains incompletely understood. Here, we show that 4β-hydroxycholesterol
(HC) (4β-HC), a liver and serum abundant oxysterol
of poorly defined functions, is a potent and selective
inducer of the master lipogenic transcription factor,
SREBP1c, but not the related steroidogenic transcription factor SREBP2. By correlating tracing of
lipid synthesis with lipogenic gene expression
profiling, we found that 4β-HC acts as a putative
agonist for the liver X receptor (LXR), a sterol sensor
and transcriptional regulator previously linked to
SREBP1c activation. Unique among the oxysterol agonists of the LXR, 4β-HC induced expression of the
lipogenic program downstream of SREBP1c and triggered de novo lipogenesis both in primary hepatocytes and in the mouse liver. In addition, 4β-HC acted
in parallel to insulin-PI3K–dependent signaling to
stimulate triglyceride synthesis and lipid-droplet
Thus, 4β-HC is an endogenous
accumulation.
regulator of de novo lipogenesis through the LXRSREBP1c axis.
Supplementary key words oxysterol • SREBP1c • liver-XReceptor • de-novo-lipogenesis • lipid droplets • insulin

All cells must achieve and maintain a balanced
composition of their internal membranes to grow,
proliferate, or adapt to sudden changes in external
conditions and nutrient availability (1). Dedicated
biosynthetic pathways mediate the synthesis of fatty
acids, sterols, phospholipids, and sphingolipids, but how
these pathways communicate with each other to coordinate their respective activities and respond to
changing metabolic needs is poorly understood (2, 3).
*For correspondence: Roberto Zoncu, rzoncu@berkeley.edu.

The liver X receptor (LXR) α and β are transcription
factors belonging to the nuclear receptor superfamily
that play key roles in maintaining lipid homeostasis in
multiple cells and organs (4–7). The LXRα and LXRβ
dimerize with the retinoid X receptor (RXR) and activate target genes that mediate cholesterol efflux from
cells, including ABC-family transporters, as well as
genes that mediate conversion of cholesterol into bile
acids in the liver to facilitate cholesterol elimination
from the body, such as cytochrome p450 7a-hydroxylase (8–10). Accordingly, mice lacking the LXRα exhibit
impaired bile acid metabolism and defective cholesterol elimination (9), along with enhanced inflammation and formation of atherosclerotic plaques (11).
Conversely, synthetic LXRα agonists have shown
promise in reducing atherosclerosis and preventing
cardiovascular disease in animal models (12–14).
Another key mediator of lipid homeostasis is the
helix-loop-helix-leucine zipper transcription factor,
SREBP1c. SREBP1c is a master regulator of biosynthesis
of fatty acids and triglycerides [collectively referred to
as de novo lipogenesis (DNL)] that is subject to tight
transcriptional and posttranslational regulation. Along
with its paralogue, the master steroidogenic transcription factor SREBP2, SREBP1c resides at the endoplasmic reticulum (ER) membrane, to which it is
anchored via a single transmembrane helix. When
cholesterol concentration in the ER membrane is low,
SREBP1c and SREBP2 are transported to the Golgi
apparatus via interaction with SREBP cleavageactivating protein, a cholesterol-sensing chaperone
that favors their loading into COPII vesicles. At the
Golgi membrane, resident proteases cleave the DNAbinding portion of SREBP1c and SREBP2 from the
transmembrane portion, enabling their translocation to
the nucleus and activation of downstream programs for
DNL and de novo steroidogenesis, respectively.
J. Lipid Res. (2021) 62 100051
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In addition to their homeostatic regulation by
cholesterol levels, the SREBPs lie downstream of
metabolic hormone signaling. For example, in the liver,
both the expression and proteolytic activation of
SREBP1c
are
stimulated
by
the
insulinphosphatidylinositol
3-kinase
(PI3K)-mechanistic
Target of Rapamycin (mTOR) pathway, as part of a
mechanism that converts excess of glucose into lipids,
which are required for energy storage (15–17). However,
the range of regulatory inputs to SREBP1c and their
respective interplay remain to be fully elucidated.
The LXRα and LXRβ were shown to directly bind to
the promoter of the SREBP1c gene and trigger activation of its downstream lipogenic genes (6). Accordingly,
synthetic LXR ligands strongly promote DNL and
increased plasma triglyceride levels (13, 18, 19),
providing evidence for cross-talk between LXR- and
SREBP1c-dependent programs.
Although the physiological significance of LXRdependent regulation of DNL through SREBP1c remains unclear, this cross-talk has important clinical
implications. In particular, LXR-dependent upregulation of SREBP1c potentially limits the usefulness of
LXR agonists to improve cholesterol metabolism, as the
resulting induction of lipogenic programs could lead to
undesirable effects, such as nonalcoholic fatty liver
disease (NAFLD), a condition that has risen to epidemic
proportions in recent years (20). Thus, understanding
how LXR-dependent activation of SREBP1c occurs and
its functional interaction with other pathways controlling lipid homeostasis such as PI3K-mTOR signaling are
key open questions.
Oxysterols are a family of metabolites that originate
from an oxygenation reaction of cholesterol. Some
oxysterols are signaling molecules involved in a wide
range of physiological processes controlling cholesterol,
glucose, and lipid metabolisms (21). Levels of oxysterols
are known to change in pathological situations such as
obesity, atherosclerosis, and Alzheimer's disease (22, 23).
A subset of oxysterols function as endogenous LXR
ligands and were shown to activate LXRα-dependent
gene expression in vitro, including those bearing hydroxyl groups in positions 4, 7, 20, 22, 24, 25, and 27 on
the cholesterol backbone (4, 24, 25). Interestingly,
although these oxysterols are considered bona fide
LXR activators, none is known to activate SREBP1c and
its downstream lipogenic programs, whereas several
oxysterols have been shown to promote LXRdependent cholesterol efflux. In contrast, synthetic
LXR ligands including T0901317 and GW3965 can
induce both cholesterol efflux and SREBP1cdependent DNL (18, 19). This leads to the question of
whether DNL is a physiologically relevant LXRdependent response, and if so, the identity of the
endogenous ligand that triggers LXR-dependent
SREBP1c expression.
Here we identify 4β-hydroxycholesterol (HC) (4βHC) as an LXR activator that selectively triggers
2
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SREBP1c activation and de novo fatty acid and triglyceride synthesis. 4β-HC promoted the expression and
proteolytic processing of SREBP1c but not of the
related steroidogenic factor SREBP2, thus triggering de
novo synthesis of fatty acids but not cholesterol. In
primary mouse hepatocytes, 4β-HC additively enhance
insulin action in promoting SREBP1c expression and
activation, leading to increased triglyceride synthesis
and storage. Thus, 4β-HC may be a novel lipogenic
factor that can shift lipid homeostasis toward triglyceride accumulation via regulation on SREBP1c.

RESULTS
4β-HC is a unique oxysterol that drives SREBP1c
gene expression
To identify oxysterol ligands that could promote
SREBP1c
expression,
we
treated
liver
carcinoma–derived Huh7 cells with a panel of oxysterols selected among the most abundant in the
bloodstream, including 4β-, 7β-, 19-, 20-, 24(S)-, 25-, and
27-HC. By quantitative PCR, several oxysterols previously identified as LXR activators, including 4β-HC, 7βHC, 24(S)-HC and 25-HC, induced the expression of a
canonical LXR target gene, ABCA1, with variable potency (Fig. 1A). In contrast, 4β-HC was the only oxysterol to induce significant upregulation of the
SREBP1c transcript (Fig. 1B). A dose-response comparison between 4β-HC and 24(S)-HC showed that 24(S)-HC
is a more potent activator than 4β-HC toward ABCA1
(Fig. 1C) and another canonical LXR gene target, ABCG1
(Fig. 1D). Conversely, 4β-HC activated SREBP1c, more
potently than 24(S)-HC (Fig. 1E). 4β-HC–mediated induction of the SREBP1c gene was enantioselective, as the
nonnatural enantiomer of 4β-HC (ent-4HC) was unable
to induce SREBP1c mRNA expression even at the
highest concentration used (20 μM) (Fig. 1F). These data
suggest that SREBP1c induction depends on unique
structural features of 4β-HC.
4β-HC induces expression and activation of SREBP1
but not SREBP2
Oxysterols such as 25- and 27-HC suppress SREBP1
and SREBP2 activation by blocking their trafficking to
the Golgi, where proteolytic processing of the SREBPs
to the mature nuclear form occurs (26, 27).
In contrast to these oxysterols, 4β-HC significantly
increased SREBP1c mRNA levels (Fig. 2A) and protein
levels in a cycloheximide-sensitive manner (Fig. 2B).
However, 4β-HC did not increase either mRNA or
protein levels of SREBP2 (Fig. 2A, B). In keeping with
the increased total levels of SREBP1c, 4β-HC increases
both cytosolic and nuclear forms of SREBP1 in a dosedependent manner, whereas levels of cytoplasmic or
nuclear SREBP2 protein levels did not change (Fig. 2C).
Consistent with previous reports (26, 27) and in contrast
to 4β-HC, 25-HC reduced the nuclear forms of both
SREBP1 and SREBP2, thereby causing the accumulation
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Fig. 1. 4β-HC is a unique LXR ligand that drives SREBP1c expression. A: Oxysterol screen for LXR target gene expression. Huh7
cells were treated with indicated oxysterols (20 μM) in 24-h time course. ABCA1 mRNA levels or (B) SREBP1c mRNA level were
measured by RT-PCR (N = 3). C: Dose-response curves of 4β-HC and 24-HC in Huh7 cells were treated for 24 h. mRNA levels of
ABCA1, (D) ABCG1, and (E) SREBP1c were measured by RT-PCR. Line plotted by nonlinear fit (N = 3). E: SREBP1c induction by 4βHC is stereospecific. Huh7 cells were treated with 4β-HC or an enantiomer of 4β-HC (ent-4HC) for 24 h in the indicated concentration (N = 3). Bars are the mean + SD. Statistical significance calculated by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001. NS, not significant; 4β-HC, 4β-hydroxycholesterol.
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Fig. 2. 4β-HC induces expression and activation of SREBP1 but not SREBP2. A: 4β-HC increases SREBP1 protein expression. Huh7
cells were treated with 20 μM 4β-HC and a translation inhibitor, cycloheximide (CHX), for 4 h followed by measurement of SREBP1
and SREBP2 mRNA (N = 3) and (B) protein level (N = 1). C: 4β-HC increases SREBP1 cytosolic and nuclear levels while not affecting
SREBP2. Huh7 cells were treated with 4β-HC or 25-HC for 24 h followed cytosolic-nuclear fractionation to measure protein level of
SREBP1 and SREBP2 cytoplasmic and nuclear levels (N = 1). Asterisk denotes unspecific band in SREBP2 nuclear blot. Bars are the
mean + SD. Statistical significance calculated by one-way ANOVA. ****P < 0.0001. Cyto, cytosolic; Nuc, nuclear; 4β-HC, 4βhydroxycholesterol.

of the unprocessed cytoplasmic form of both proteins
but without transcriptional upregulation (Fig. 1B).
These data suggest that, unlike other oxysterols that
function as inhibitors of both SREBP1c and SREBP2,
4β-HC is a specific inducer of SREBP1c expression and
activation.
4β-HC induce lipogenic programs through the LXRs
Along with other oxysterols, 4β-HC was previously
shown to activate LXRα-dependent transcription in
luciferase assays in vitro, supporting its role as a putative LXR ligand (4, 28). In turn, the LXR transcriptionally activates SREBP1c by directly binding to its
promoter region (6). Combining these observations, we
thus hypothesized that 4β-HC may transcriptionally
activate SREBP1c and its downstream lipogenic programs via the LXR. Consistent with this possibility,
cotreating cells with 4β-HC together with an LXR
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antagonist (GSK-2033) abolished 4β-HC–dependent induction of SREBP1c gene expression (Fig. 3A).
The effect of 4β-HC on SREBP1c induction was
additive with an RXR ligand, 9-cis-retinoic acid.
Moreover, coincubation of 4β-HC with the LXR
agonist, GW3965, used at concentrations that activate
the LXR maximally, caused no additional increase in
SREBP1c expression over GW3965 alone (Fig. 3A).
siRNA-mediated knockdown of either the LXRα or
LXRβ (both of which are expressed in Huh7 cells)
largely abolished 4β-HC–dependent SREBP1c mRNA
expression (Fig. 3B). Interestingly, we noticed that 4βHC treatment increased LXRα protein levels, a stabilizing effect observed for other established LXR ligands (29) (Fig. 3C). Together, and combined with
previous reports these data support the hypothesis
that 4β-HC induces SREBP1c gene expression by
acting as an LXR agonist.

Relative mRNA level

****
**

2
**

0

L

+

si
LX
R

si
LX
R

a

b

O
N

4β-HC: -

4β-HC
1.5

-

+

-

+

LXRa

75kDa

LXRb
50kDa
50kDa

0.5

Actin
40kDa

C
si

C

FASN

R
b
si
LX

TR

R
a

L

(L
XR

)

on
tro
l
4β
-H
94β
C
R
-H
A
4β
C
(R
-H
+
XR
C
9
)
+G -RA
SK
(R
XR
-2
03
)
3
4β
G
(
W
LX
-H
39
R
C
)
65
+
G
(L
W
XR
39
)
65

0.0

D

50kDa

*

1.0

si
LX

Relative mRNA level

Vehicle

2.0

****

***

O

****

6

4

C

SREBP1c

NS

TR

B
SREBP1c

si
C

A

LPIN1

SCD1

E
de-novo Lipogenesis

C16:0/C16:0/C16:0 TAG

39
65
W

39
W
G

0.5

G

65

C

C
H

-H
24

l
tro

39
W
G

4β
-

65

C

C
-H

-H
24

l
4β

tro
on
C

*

1.0

24
H
C

0.5

*

1.5

-H
C

1.0

0.0

65

C

39

-H

W
G

H

tro

C
24

4β
-

on
C

1.5

**

2.0

4β

0.5

**

on
tro
l

1.0

0.0
l

0.0

1.5

on

0.5

**

**

C

1.0

Relative mRNA level

***

1.5

2.0

**

C

2.0

***
Relative mRNA level

Relative mRNA level

***

C13 incorporated TAGs (a.u.
(a.u.)

C16:0/C18:1/C16:0 TAG

2.0
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We next compared the ability of 4β-HC to induce
SREBP1c-dependent lipogenic programs with that of
the LXR agonist, GW3965. Fatty acid synthase (FASN),
Stearoyl-CoA desaturase (SCD1) and Lipin1 (LPIN1) are
validated SREBP1c downstream targets in Huh7 cells
(30, 31). Treatment with either 4β-HC or GW3965
significantly increases the expression of these genes
(Fig. 3D). In contrast, 24-HC, another putative LXR
ligand that failed to induce SREBP1c in our hands
(Fig. 1B, E), had minimal or no effect on these SREBP1c
target genes (Fig. 3D).
Previous work had shown that GW3965 induces
FASN to a greater extent than the 1.6-fold we observed
in Huh7 (32). Huh7, a hepatocellular carcinoma line, is
known to hyperactivated DNL to supply membranal
lipids required for rapid division and growth (33, 34).
We speculate that the modest increase in FASN by
GW3965 or 4β-HC is due to already elevated baseline
expression that cannot be increased much further. To

further substantiate the prolipogenic effect of 4β-HC,
we directly measured DNL by C13 incorporation into
triglycerides using LC/MS. Similarly to lipogenic gene
induction, both GW3965 and 4β-HC had a modest but
statistically significant 1.5-fold increase in C13-labeled
C16:C16:C16 TAG, or trending toward significance for
C16:C18:C16 TAG, whereas 24-HC caused no significant
change (Fig. 3E). Combined, these data suggest that the
prolipogenic action of 4β-HC is comparable, in mechanism and potency, to known LXR agonists.
4β-HC induces lipid-droplet formation and
triglyceride accumulation
In keeping with the ability of 4β-HC to upregulate
fatty acid biosynthetic genes via SREBP1c, treating
Huh7 cells with 4β-HC (but not with its unnatural
enantiomer, ent-4HC) for 72 h resulted in marked
accumulation of lipid droplets (LDs), as revealed by
staining with the lipophilic dye BODIPY 493/503
4βHC coordinates cholesterol with fatty acid metabolism
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(Fig. 4A, B). LD accumulation induced by 4β-HC was
suppressed by simultaneous treatment with a FASN
inhibitor, TVB-3166, or with the LXR inhibitor GSK2033. Measurement of triglyceride content in cell extracts confirmed the ability of 4β-HC to induce triglyceride accumulation, albeit with lower potency than
the LXR agonist GW3965, whereas cholesterol levels
remained unchanged (Fig. 4C). Consistent with the
BODIPY staining, both LXR and FASN inhibitors hindered 4β-HC–induced triglyceride accumulation
(Fig. 4C). Moreover, as seen with SREBP1c induction, the
ent-4HC failed to induce triglyceride accumulation
(Fig. 4C). Thus, 4β-HC is sufficient to induce the formation of triglyceride-containing LDs in an LXR- and
FASN-dependent manner in cell culture.
Next, we tested the effect of 4β-HC on in vivo lipogenesis by feeding mice a normal diet supplemented
with either 4β-HC or GW3965. After 7 days, the livers
were harvested, LDs were assessed by BODIPY staining,
and the liver lipid content (normalized to protein mass)
was measured. Consistent with the results in Huh7 cells,
4β-HC significantly increased the size and number of
LDs in liver sections (Fig. 4D) and liver triglyceride
content (Fig. 4E), albeit with lower potency than the
synthetic LXR agonist, GW3965. Collectively, these data
suggest that 4β-HC is a prolipogenic factor that can
increase liver lipid content in vivo.
4β-HC acts in parallel to insulin-PI3K signaling to
drive SREBP1c expression
Insulin is a key hormone that drives SREBP1c transcription, proteolytic processing, and DNL in the postprandial state. Insulin regulates SREBP1c transcription
via poorly understood mechanisms, which include AKTdependent transcriptional downregulation of Insig-2a,
the ER-retention factor that blocks translocation of
SREBP cleavage-activating protein-SREBP1c to the Golgi
(35, 36). The LXR was shown to be required for insulindependent activation on SREBP1c (37), but whether and
how insulin activates LXR is not understood.
To interrogate the relationship between 4β-HC and
insulin signaling in driving SREBP1c transcription and
processing, we used an insulin-responsive primary
mouse hepatocyte (38). In these cells, stimulation with
either 4β-HC or insulin alone increased the mRNA
levels of SREBP1c, while combined 4β-HC and insulin
increased SREBP1c mRNA levels additively [as previously shown for LXR agonists (37)] (Fig. 5A).
Interestingly, treatment with PI3K or mTORC1
inhibitors abolished SREBP1c induction by both
insulin and 4β-HC (Fig. 5A), raising the possibility of a
‘coincidence detection’ model, in which a minimal
amount of both insulin-PI3K-mTORC1 and 4β-HC

signaling must be present for SREBP1c induction to
occur.
Similar to their effects on transcriptional induction,
insulin and 4β-HC stimulated proteolytic processing of
SREBP1c in an additive manner (Fig. 5B). 4β-HC did not
affect AKT phosphorylation significantly, suggesting
that insulin-PI3K-AKT and 4β-HC signaling act in
parallel and converge at the level of the SREBP1 gene
promoter (Fig. 5B and supplemental Fig. 1A).
Consistent with previous reports, we also detected a
marked decrease in Insig-2a mRNA in insulinstimulated hepatocytes (Fig. 5C). In contrast, 4β-HC
caused a mild increase of Insig-2a mRNA levels, and
combined insulin and 4β-HC was similar to insulin
alone, suggesting Insig-2a downregulation is not
required for 4β-HC–dependent SREBP1c activation
(Fig. 5C).
To further probe possible connections between
insulin-PI3K and 4β-HC-LXR signaling, we tested
whether insulin signaling promotes 4β-HC synthesis.
Previous reports had shown that in humans, 4β-HC has
a very slow kinetics, with an extremely long half-life in
plasma (60 h) (39). Pharmacological induction of the
main 4β-HC–synthesizing enzyme, cytochrome P450
3A, doubles 4β-HC concentration in human plasma in
8 days (40), a very different pattern from insulin, which
peaks within 1–2 h after a meal and drops in between.
On the other hand, in vitro work in primary rat hepatocytes led to the hypothesis that insulin signaling may
produce an unknown LXR ligand that, in turn, induces
SREBP1c (37). To test the possibility of insulindependent 4β-HC production, we compared 4β-HC
levels in the liver of mice that were either fasted or
refed. Although mice that were refed showed significant induction of SREBP1c transcription, consistent
with SREBP1c regulation by insulin (Fig. 5D), the levels
of 4β-HC did not increase accordingly in the liver
(Fig. 5E) or serum (Supplemental Fig. 1B). Collectively,
these data suggest that insulin does not induce 4β-HC
production according to fasting/feeding cycles and
that 4β-HC most likely acts in parallel to insulin-PI3K
signaling in driving SREBP1c transcription and
SREBP1c-dependent DNL (Fig. 5F).

DISCUSSION
Here we identify 4β-HC as a unique oxysterol that
activates SREBP1c expression and promotes lipogenic
gene programs, resulting in induction of fatty acid
biosynthesis and cellular accumulation of triglycerides
in LDs both in cell culture and in vivo. Our results are
most consistent with a model in which 4β-HC acts in
parallel to insulin-PI3K-mTOR signaling, and the two

marked in green and antagonists are marked in red. Bars are the mean + SD. Statistical significance calculated by one-way
ANOVA.*P < 0.05, **P < 0.01, ****P < 0.0001. ent-4HC, stereo enantiomer-4HC, FASNi, TVB-3166; LXRi, GSK-2033; 4β-HC, 4βhydroxycholesterol.
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Fig. 5. 4β-HC acts in parallel to insulin-PI3K signaling to drive SREBP1c expression. A: SREBP1c transcription is additive by 4β-HC and
insulin. Primary hepatocytes were treated overnight with vehicle or 5 μM 4β-HC followed with 6 h stimulation with combinations of
insulin, PI3K inhibitor (LY294002), or rapamycin. The SREBP1c mRNA level was measured by RT-PCR (N = 4). B: 4β-HC and insulin
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Primary hepatocytes were treated with 4β-HC and insulin as described in (A) followed by RT-PCR measurement of Insig-2a mRNA level
(N = 4). D: Insulin does not induce 4β-HC synthesis. Mice were fasted for 16 h and then refed for 4 h, followed by liver extraction and RTPCR for SREBP1c mRNA level (N = 4) and (E) 4β-HC levels by MS (N = 5). F: Model; the 4β-HC-LXR pathway acts in parallel to the
insulin-PI3K pathway to drive SREBP1c expression in an additive fashion. **P < 0.01, ***P < 0.001, ****P < 0.0001.
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pathways have additive effects on SREBP1c activation.
A simple mechanism that explains the additive effect is
that the SREBP1c promoter contains both an LXRbinding element and an SREBP-binding element and
that transcription can be stimulated by the two transcription factors independently (41). However, the
observation that inhibition of PI3K-AKT signaling also
blunts 4β-HC–dependent SREBP1 induction (Fig. 5A)
points to a possible ‘coincidence detection’ model,
where at least some signaling by one input (i.e., insulin)
has to be present for the other input (4β-HC) to be
effective, and vice versa. From a temporal standpoint,
4β-HC kinetics suggest that it stimulates SREBP1c
expression in a chronic manner, whereas insulin acts
acutely in the postprandial state.
A recent publication by Salonurmi et al. (42) showed
that 4β-HC induces cholesterol efflux from peripheral mononuclear cells in vivo via transcriptional
upregulation of ABCA1 and concomitant suppression
of influx transporters. In our hands, 4β-HC did not
induce ABCA1 expression in primary hepatocytes
(supplemental Fig. 1C), whereas its induction was
observed in Huh7 cells. Thus, 4β-HC–dependent
regulation of cholesterol efflux versus DNL may be
cell type specific and tied to different physiological
settings.
Several groups using different animal models (mice,
rats, rabbits, and swine) had all observed that 4β-HC
levels increase when animals are fed a high cholesterol
diet (43–46), whereas a high-fat but with low-cholesterol
diet reduces 4β-HC levels in mice (47). Dietary cholesterol was shown to increase SREBP1c expression in an
LXR-dependent manner (6, 9). Furthermore, genetically disrupting hepatic cholesterol synthesis through
SREBP2 KO also causes SREBP1c downregulation, which
can be rescued by an LXR agonist (48). This study also
determined that 4β-HC levels are decreases in young
SREBP2-null mice, defining a correlation between
SREBP2-dependent cholesterol synthesis, 4β-HC levels,
and SREBP1c expression. Together with this published
literature, our results strongly suggest that 4β-HC may
be the cholesterol-derived molecule that induces
SREBP1c activation via the LXR.
An important question is why 4β-HC is the sole
oxysterol ligand of LXRs to activate SREBP1 expression
in our hands. Several possibilities can be envisioned.
The LXR-RXR heterodimer can recruit coactivators
(PGC-1α, TRRAP, ACS-2, p300, SRC-1) and corepressors
(NCoR, SMRT) to the promoters of target genes in a
ligand-dependent manner (49–53), but whether all LXR
ligands are equally effective in recruiting specific
combinations of cofactors is unclear. Supporting this
model was an observation in macrophages that the
ability of the LXR to recruit RNA polymerase II to
SREBP1c promoter requires a specific LXR ligand, while
recruitment of RNA polymerase II to the ABCA1 promoter is more promiscuous (29). Thus, 4β-HC may be
able to direct a unique set of coactivators and RNA

polymerase II to the SREBP1c promoter, resulting in its
activation.
Consistent with previous reports, the synthetic LXR
agonist GW3965 was also able to trigger SREBP1 expression (18, 19). Synthetic LXR agonists are generally more
potent than natural LXR ligands, possibly reflecting
higher affinity for the ligand-binding site of the LXR. By
analogy, 4β-HC may bind to the LXR with higher affinity
than other oxysterol ligands. In turn, higher affinity may
translate into longer residence time on the SREBP1c
promoter DNA, a possible prerequisite for its efficient
activation.
Our data point to the importance of the enzyme that
produces 4β-HC, Cyp3A4 (Cyp3A11 in mice) (54), as a
crucial regulator of lipogenesis. Consistent with that,
several groups have reported that increased Cyp3A4
expression by overexpressing its activator, pregnane X
receptor, correlated with increases in lipogenic gene
expression and liver triglyceride levels (55, 56).
Conversely, decreased Cyp3A4 expression (57) or its
pharmacological inhibition (58) was associated with
lower lipogenic gene expression and liver triglyceride
levels. Taken together, these data suggest that Cyp3A4
and 4β-HC may regulate diet-induced lipogenic genes
and liver triglyceride levels.
From a more clinical perspective, 4β-HC might have
an aggravating effect on the development of NAFLD.
NAFLD is characterized by elevated liver triglycerides
not due to alcohol consumption or any other known
causes (59). Elevated triglyceride levels are associated
with LXR and SREBP1c upregulation in NAFLD (60).
Patients with NAFLD show a significant increase in 4βHC plasma levels compared with healthy patients (61).
Thus, it is plausible that elevated 4β-HC levels could be
an unrecognized driver of triglyceride accumulation in
NAFLD. It would be interesting to determine the effect
of pharmacologic Cyp3A4 inhibition on disease progression in patients with NAFLD.
In conclusion, this work highlights a role for 4β-HC,
which was long viewed as an ‘orphan’ oxysterol, in
regulating lipid metabolism in the liver together with
insulin. Future work, dissecting the role of 4β-HC in
other organs and in different pathological settings, will
provide a full picture on the function and significance
of this highly abundant oxysterol.

MATERIALS AND METHODS
Materials
Reagents were purchased from the following sources. Antibodies used are as follows: SREBP1 (2A4, Santa Cruz
Biotechnology), SREBP2 (30682, Abcam), LXRα (PP-PPZ041200, R&D systems), LXRβ (K8917, R&D systems), phospho-T308
AKT (C31E5E), AKT (11E7) (Cell Signaling Technology).
Drugs used are as follows: Cycloheximide (Cell Signaling
Technology) was used at 10 μg/ml. 9-cis-retinoic acid (Sigma)
was used at 50 μM. The LXR antagonist GSK-2033 (Axon
Medchem) was used at 500 nM. The LXR agonist GW3965
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Protein extraction and Western blot

(Fisher Scientific) was used at 500 nM. PI3K inhibitor,
LY294002 (Cell Signaling Technology), was used at 10 μM.
Rapamycin was used at 100 nM and received as a gift from
David Sabatini. Methyl-beta-cyclodextrin was purchased from
Sigma. All sterols except for custom-synthesized ent-4β-HC
(see below) were purchased from Steraloids. C13 glucose was
purchased from Cambridge Isotope Laboratories.

Cells were harvested with the RIPA buffer supplemented
with Phosphatase inhibitor and protease inhibitor (10 mM Tris
Cl (pH 8.0), 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, 10 mM Na-PPi, 10 mM Na-Betaglycerophosphate), sonicated with Bioruptor (Diagenode), and
normalized using the BCA kit (Thermo Scientific).

Sterol: methyl-beta-cyclodextrin precomplexing

Knockdown using siRNA

All sterols were made to 50 mM stocks in ethanol. To
deliver the sterols to cells, 1.25 mM sterol was complexed with
25-mM methyl-beta-cyclodextrin and vortexed until the solution was clear. Sterols were added to the media in an indicated concentration and incubation time. Control samples
were treated by adding the same volume of ethanol to
methyl-beta-cyclodextrin, which then was delivered to cells in
the same corresponding volume.

siRNA ON-TARGET plus smart pool against LXRα (cat# L003413-00-0005), LXRβ (cat# L-003412-02-0005), or nontargeted siRNA ON-TARGETplus Non-targeting Pool (cat#
D-001810-10-05) was purchased from Dharmacon. Five
micromolar siRNA was mixed with 5 μl Lipofectamine
RNAiMAX (Life Technologies) in Opti-MEM (Gibco). siRNA
is added to preplated Huh7 (105 cells/6 cm plate) in regular
media without penicillin streptomycin for 5 h followed by
replacement to regular media for 72 h.

Cell culture
Huh7 cells were maintained on DMEM (5 g/l glucose +
glutamine, Gibco) supplemented with 10% FBS (VMR) and p/s
(Gibco). Lipid-depleted serum (LDS) was made as described (62).
For assays, on day one; 105 cells were plates in 6 cm plates. On
day 2, media was changed to 1% LDS and 1 g/l glucose DMEM.
On day 3; plates were spiked with precomplexed sterols for
indicated times, concentrations, and additional compounds.
Primary mouse hepatocytes were purchased from the
UCSF liver center. The isolation protocol is based on the
study by Li, Brown, and Goldstein (63) and adjusted in the
following manner. Mice were fasted overnight before
isolation. Hepatocytes were isolated by the perfusion protocol (64) and plated at density of 7 × 105/well on 6-well
collagen-coated plates (Corning) in DMEM supplemented
with 10% FBS. Once cells adhere, the media was replaced to
Medium 199 (GIBCO) containing 100 nM dexamethasone
(Sigma), 100 nM 3,3,5-triiodo-L-thyronine (T3, Sigma), and
Insulin-Transferrin-Selenium (Gibco). Next day, the same
media was used without Insulin-transferrin-Selenium to
assay insulin, 4β-HC, and inhibitors at indicated times and
concentrations.

LD microscopy
Huh7 were plated on a coverslip coated with fibronectin
(Corning) and treated as indicated with sterols and drugs. Cells
were fixed with paraformaldehyde and stained with 1 μg/ml
BODIPY 493/503 for 1 h. Coverslips were mounted with VECTASHIELD with DAPI (Vector Laboratories) and imaged on a
spinning disk confocal system (Andor Revolution on a Nikon
Eclipse Ti microscope). The BODIPY signal was measured using
ImageJ and normalized by the number of nuclei.

Triglyceride and cholesterol measurements
Liver samples were powdered with a pestle and mortar
and lysed in the RIPA buffer. Huh7 cells were also harvested
in the RIPA buffer. Five microliters of the samples was used
to measure triglyceride using Triglyceride Infinity (Thermo
Fisher) or cholesterol using the Amplex red cholesterol
measuring kit (Invitrogen) in a clear 96-well sample. The
BCA kit (Thermo Scientific) was used for normalization of
the protein level. Absorbance and fluorescence were
measured by the PerkinElmer Envision Multilabel plate
reader.

Real-time PCR analysis for gene expression

C13 incorporation into triglycerides

RNA was extracted using the RNeasy kit (Qiagen). One
microgram of RNA was reverse-transcribed using Super
Script III (Invitrogen). Quantitative PCR was performed using
Ssoadvanced (Bio-Rad) in StepOnePlus (ABI). The list of
primers is in Table 1.

Huh7 cells were seeded at 200K per 6-cm plates. The next
day, DMEM media with glutamine, containing 5 mM C13
glucose (Cambridge Isotope Laboratories) and 1% LDS
including oxysterols and the LXR agonist were added for
24 h. C12 glucose–treated plates were used as reference. Cells

TABLE 1.
Gene

TBP
SREBP1c
FASN
SCD1
ABCA1
ABCG1
LPIN1
SREBP2
SREBP1C
SREBP2
INSIG-2A
TBP

10

RT-PCR primers

Species

Forward

Reverse

Human
Human
Human
Human
Human
Human
Human
Human
Mouse
Mouse
Mouse
Mouse

TTGTACCGCAGCTGCAAAAT
GCGCCTTGACAGGTGAAGTC
CTTCAAGGAGCAAGGCGTGA
TCTAGCTCCTATACCACCACCA
TGTTCGCGGCCCTCAT
TGCAATCTTGTGCCATATTTGA
CCAGCCCAATGGAAACCTCC
GAGCTGGGTGGTCTGGAG
CGGAAGCTGTCGGGGTAG
GCGTTCTGGAGACCATGGA
TGTGAGCTGGACTAGCTTGCT
ACCCTTCACCAATGACTCCTATG

TATATTCGGCGTTTCGGGCA
GCCAGGGAAGTCACTGTCTTG
ACTGGTACAACGAGCGGATG
TCGTCTCCAACTTATCTCCTCC
CGAGATATGGTCCGGATTGC
CCAGCCGACTGTTCTGATCA
AGGTGCATAGGGATAACTTCCTG
TTGCAGCATCTCGTCGATGT
GTTGTTGATGAGCTGGAGCA
ACAAAGTTGCTCTGAAAACAAATCA
CCTAAGCCGTAAAACAAAATG
ATGATGACTGCAGCAAATCGC
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Cryosectioning and fluorescent histochemistry

were washed twice with ice-cold PBS and scraped, and pellets
were snap-frozen and kept in −80◦ C for later analysis. Lipid
extraction and analysis by LC/MS was performed as
described (65).

Liver samples were fixed using 4% (v/v) paraformaldehyde
overnight at 4◦ C. The next day, samples were cryopreserved
using sterile-filtered 30% sucrose (w/v) in dulbecco’s phosphate buffered saline (DPBS) (Gibco, 14190-144). After 3 days,
each sample was placed in a 1:1 30% sucrose:Neg-50 (RichardAllan Scientific) solution and incubated overnight at 4◦ C. The
samples were frozen on dry ice using undiluted Neg-50
at −50◦ C and stored at −80◦ C until sectioning. Sequential
20 μM thick sections were obtained from each sample using a
Leica CM3050S cryostat.
For nuclei and LD labeling, sectioned tissue was washed three
times at room temperature in DPBS for 5 min each. Afterward,
DPBS containing 10 μM BODIPY (Invitrogen, #D3922) was
placed on the samples and incubated for 30 min at room temperature in the dark. Next, the slides were washed with DPBS
twice before incubating in DPBS containing 5 μg/ml DAPI
(Invitrogen, D1306) for 10 min at room temperature in the dark.
After DAPI staining, the slides were washed three times in DPBS
for 5 min each before being mounted using SlowFade Diamond
antifade (Invitrogen, #S36972) and sealing with nail polish
overnight. Slides were imaged immediately using a Zeiss LSM710

Husbandry and diets
All mouse procedures were performed and approved
under the University of California, Berkeley Animal Care
and Use Committee. Ten-week-old C57BL/6J male mice
were purchased from the Jackson Laboratory and housed
for one week in our facility under standard conditions
before experiments were performed. Free access to water
and chow (Lab Diets, #3038) was provided throughout this
acclimation period. Afterward, mice were placed on a diet
with 50 mg/kg/day 4β-HC or LXR agonist GW3965
10 mg/kg/day for 7 days. Powdered 10% by kCal fat diet
(Research Diets Inc. #D12450J) was used as the base of
each treatment food, forming pellets that were dried
overnight at room temperature in a laminar flow hood.
After 7 days, mice were euthanized using CO2 and cervical dislocation.
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confocal microscope. Images were developed using the IMARIS
(Bitplane) image analysis software suite.

Synthesis of ent-4β-HC
ent-steroid 2. ent-Testosterone (1) was prepared as described
previously [(66); see also references therein]. To a solution of
ent-testosterone (1, 3.8 g, 13.2 mmol) in acetic anhydride (80 ml)
was added NaI (7.92 g, 52 mmol) and trimethylsilyl chloride
(5.8 ml, 52 mmol) at 0◦ C under N2. After addition, the reaction
was allowed to warm to room temperature for 2 h. The reaction was added to Et3N (40 ml) in diethyl ether (100 ml). The
ether solution was washed with brine (50 ml × 4) and aqueous
NaHCO3 (50 ml × 2) and dried over Na2SO4. After filtration,
the solvent was removed under reduced pressure and the
residue was purified by flash column chromatography (silica
gel eluted with 25% ethyl acetate (EtOAc) in hexanes) to give
ent-steroid 2 (3.05 g, 70%): 1H NMR (400 MHz, CDCl3) δ
5.33–5.32 (m, 1H), 4.60 (t, J = 8.3 Hz, 1H), 3.52–3.47 (m, 1H),
2.30–0.90 (m), 2.02 (s, 3H), 1.00 (s, 3H), 0.79 (s, 3H); 13C NMR
(100 MHz, CDCl3) δ 171.2, 140.9, 121.1, 82.7, 71.5, 51.0, 50.0, 42.3,
42.2, 37.2, 36.7, 36.5, 31.6, 31.5, 31.4, 27.4, 23.5, 21.1, 20.5, 19.3, 11.8.
ent-steroid 3. ent-Steroid 2 (3.05 g, 4.04 mmol) was dissolved
in CH2Cl2 (50 ml) and cooled to 0◦ C. (i-Pr)2EtN (3.0 ml) and
ClCH2OMe (1.35 ml, 18.0 mmol) were added, and the reaction
was stirred at room temperature for 16 h. The reaction was
made basic by adding aqueous NaHCO3 solution, and the
product was extracted into CH2Cl2. The combined extracts
were washed with brine, dried over Na2SO4, filtered, and
solvent removed to give a viscous liquid that was purified by
flash column chromatography (silica gel eluted with 10%
EtOAc in hexanes) to give ent-steroid 3 as a colorless liquid
(2.65 g, 77%): 1H NMR (400 MHz, CDCl3) δ 5.33–5.32 (m, 1H),
4.65 (s, 2H), 4.59 (t, J = 8.2 Hz, 1H), 3.39–3.35 (m, 1H), 3.34 (s, 3H),
2.35–0.89 (m), 2.01 (s, 3H), 0.99 (s, 3H), 0.78 (s, 3H); 13C NMR
(100 MHz, CDCl3) δ 171.0, 140.7, 121.2, 94.6, 82.6, 76.7, 55.0, 50.9,
50.0, 42.3, 39.4, 37.1, 36.7, 31.6, 31.4, 28.8, 27.4, 23.5, 21.0, 20.4, 19.3,
11.8.
ent-steroid 4. To a solution of ent-steroid 3 (2.65 g,
7.05 mmol) in methanol (60 ml), K2CO3 (4.0 g) was added at
room temperature. The mixture was refluxed for 16 h.
Methanol was removed under reduced pressure, and the
residue was purified by flash column chromatography (silica
gel eluted with 25% EtOAc in hexanes) to give ent-steroid 4
(2.31 g, 99%): 1H NMR (400 MHz, CDCl3) δ 5.32–5.30 (m, 1H),
4.64 (s, 2H), 3.61 ( t, J = 8.6 Hz, 1H), 3.40–3.34 (m, 1H), 3.33 (s, 3H),
2.31–0.87 (m), 0.95 (s, 3H), 0.72 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 140.7, 121.3, 94.5, 81.6, 76.7, 55.0, 51.2, 50.2, 42.6, 39.4,
37.2, 36.7, 36.5, 31.8, 31.4, 30.3, 28.8, 23.3, 20.5, 19.3, 10.9.
ent-steroid 5. To a solution of ent-steroid 4 (1.5 g, 4.54 mmol)
in CH2Cl2 (60 ml), Dess–Martin periodinane (2.5 g, 6 mmol)
was added at room temperature. After 1 h, water (50 ml) was
added, the product was extracted into CH2Cl2 (150 ml × 3), and
the combined extracts were washed with brine (50 ml × 2).
The organic layer was dried over Na2SO4 and filtered and the
solvents were removed. The residue was purified by flash
column chromatography (silica gel eluted with 10% EtOAc in
hexanes) to give ent-steroid 5 (1.5 g, 100%): 1H NMR (400 MHz,
CDCl3) δ 5.39–5.38 (m, 1H), 4.68 (s, 2H), 3.45–3.38 (m, 1H), 3.37 (s,
3H), 2.49–0.98 (m), 1.03 (s, 3H), 0.88 (s, 3H); 13C NMR (100 MHz,
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CDCl3) δ 221.0, 140.9, 120.9, 94.7, 76.7, 55.1, 51.7, 50.2, 47.5, 39.5,
37.1, 36.8, 35.8, 31.4, 31.3, 30.8, 28.8, 21.8, 20.3, 19.3, 13.5.
ent-steroid 6. A solution of freshly prepared sodium ethoxide (sodium 0.4 g, 15 mmol dissolved in ethanol 15 ml) was
added dropwise slowly to a solution of ent-steroid 5 (1.5 g,
4.54 mmol) and triethyl phosphonoacetate (3.44 g, 15 mmol) in
anhydrous ethanol (25 ml) under N2 while stirring at 35–40◦ C.
After addition, the reaction was refluxed for 16 h. After
cooling to room temperature, the ethanol was removed and
the residue was dissolved in ether, which was washed with
water, dried over Na2SO4, and filtered. The solvent was
removed, and the residue was purified by flash column
chromatography (silica gel eluted with 10% EtOAc in hexanes)
to give ent-steroid 6 (1.68 g, 87%): 1H NMR (400 MHz, CDCl3) δ
5.52 (s, 1H), 5.35–5.34 (m, 1H), 4.66 (s, 2H), 4.15–4.09 (m, 2H),
3.43–3.33 (m, 1H), 3.35 (s, 3H), 2.84–2.79 (m, 2H), 2.36–0.93 (m),
1.01 (s, 3H), 0.82 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 176.1, 167.3,
140.7, 121.3, 108.6, 94.6, 76.7, 59.4, 55.1, 53.7, 50.2, 46.0, 39.5, 37.2,
36.8, 35.1, 31.6, 31.5, 30.4, 28.8, 24.4, 20.9, 19.3, 18.2, 14.3.
The reaction sequence reported below that converts
ent-steroid 6 into ent-steroid 16 (ent-VP1-001) is based on that
reported previously for the preparation of the natural
stereoisomer of ent-steroid 16 (67).
Unpuriﬁed ent-steroid 7. To a solution of ent-steroid 6 (1.4 g,
3.48 mmol) in EtOAc (150 ml), PtO2 (15 mg) was added at room
temperature. Hydrogenation was carried out under 20 psi for
6 h. The solvent was removed, and the residue was purified by
flash column chromatography (silica gel eluted with 10%
EtOAc in hexanes) to give unpurified ent-steroid 7 (1.4 g,
100%): 1H NMR δ 4.63–4.60 (m, 1H), 4.08–4.03 (m, 2H), 3.48–3.32
(m, 1H), 3.31 (s, 3H), 2.34–0.57 (m), 0.76 (s, 3H), 0.54 (s, 3H); 13C
NMR δ 176.1, 140.7, 121.3, 94.4, 76.2, 60.0, 55.3, 55.0, 54.5, 46.9,
44.9, 42.1, 37.4, 37.0, 35.6, 35.5, 35.3, 35.2, 32.1, 28.7, 28.1, 24.4, 20.9,
14.2, 12.5.
Unpurified ent-steroid 7 contains minor amounts of the entsteroid in which the Δ5 double bond has been hydrogenated.
This saturated ent-steroid could not be removed easily by
chromatography on silica gel. To separate the two compounds
chromatographically, ent-steroid 7 was converted first into entsteroid 8 and then into ent-steroid 9, which is easily purified.
ent-Steroid 9 was then converted back via ent-steroid 8 into entsteroid 7 and then subsequently into ent-steroid 10.
Unpuriﬁed ent-steroid 8. Acetyl chloride (2 ml) was slowly
added to unpurified hydrogenation product ent-steroid 7
(1.4 g, 3.48 mmol) in ethanol (30 ml) at room temperature.
After 2 h, water was added and the product was extracted into
CH2Cl2 (100 ml × 2). The combined extracts were dried over
Na2SO4 and filtered, and the solvent was removed under
reduced pressure. The residue was purified by flash column
chromatography (silica gel eluted with 25% EtOAc in hexanes) to give unpurified ent-steroid 8 (1.2 g): 1H NMR (400 MHz,
CDCl3) δ 5.35–5.34 (m, 1H), 4.13–4.07 (m, 2H), 3.55–3.47 (m, 1H),
2.38–0.81 (m), 1.10 (s, 3H), 0.61 (s, 3H); 13C NMR (100 MHz, CDCl3)
δ 173.9, 140.8, 121.5, 71.6, 60.1, 55.5, 50.3, 46.8, 42.2, 41.9, 37.3, 37.2,
36.5, 35.2, 31.9, 31.8, 31.6, 28.1, 24.5, 20.8, 19.4, 14.2, 12.4.
ent-steroid 9. To a solution of unpurified ent-steroid 8 (1.2 g,
3.33 mmol) in diethyl ether (100 ml) and acetic acid (5 ml), Br2
in HOAc (3 ml) was added slowly until brown color persisted.
After 5 min, aqueous Na2S2O3 was added and the reaction
became colorless. EtOAc (100 ml) was added, and the EtOAc
solution was washed with aqueous NaHCO3 (50 ml × 2), brine

(50 ml), and dried over anhydrous Na2SO4. After filtration,
the solvent was removed under reduced pressure, and the
residue was purified by flash column chromatography (silica
gel eluted with 20% EtOAc in hexanes) to give ent-steroid 9
(1.4 g, 81%): 1H NMR (400 MHz, CDCl3) δ 4.82–4.81 (m, 1H),
4.44–4.37 (m, 1H), 4.12–4.06 (m, 2H), 2.72–1.08 (m), 1.43 (s, 3H),
0.62 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 173.8, 89.6, 68.9, 60.1,
56.0, 54.0, 47.6, 46.6, 45.6, 42.2, 42.0, 37.2, 37.0, 36.7, 35.2, 30.9,
30.1, 28.0, 24.2, 21.0, 20.3, 14.2, 12.7.
Puriﬁed ent-steroid 8. Zinc dust (6.0 g) was added to a solution of ent-steroid 9 (1.4 g, 2.7 mmol) in HOAc (20 ml) and
EtOAc (30 ml) at room temperature. After 16 h, the mixture
was filtered through Celite and washed with EtOAc (200 ml).
The solvent was removed under reduced pressure, and the
residue was purified by flash column chromatography (silica
gel eluted with 25% EtOAc in hexanes) to give purified entsteroid 8 (925 mg, 95%): 1H NMR (400 MHz, CDCl3) δ 5.26–5.25
(m, 1H), 4.06–4.01 (m, 2H), 3.85 (s, br, 1H), 3.47–3.40 (m, 1H),
2.31–0.73 (m), 0.93 (s, 3H), 0.54 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 173.8, 140.7, 121.1, 71.2, 60.0, 55.4, 50.1, 46.6, 41.9, 41.7,
37.1, 37.0, 36.3, 35.0, 31.7, 31.7, 31.2, 27.9, 24.3, 20.6, 19.2, 14.0, 12.2.
Puriﬁed ent-steroid 7. Purified ent-steroid 8 (925 mg,
2.57 mmol) was dissolved in CH2Cl2 (20 ml) and cooled to 0◦ C.
(i-Pr)2EtN (1.3 ml, 7.5 mmol) and ClCH2OMe (0.45 ml,
6.0 mmol) were added, and the reaction was stirred at room
temperature for 16 h. The reaction mixture was made basic by
adding aqueous saturated NaHCO3 solution and the product
extracted into CH2Cl2. The combined extracts were washed
with brine, dried over anhydrous Na2SO4, and the solvent
removed to give a viscous liquid that was purified by flash
column chromatography (silica gel eluted with 20% EtOAc in
hexanes) to give purified ent-steroid 7 as a colorless liquid
(1.02 g, 98%): 1H NMR (400 MHz, CDCl3) δ 5.34–5.33 (m, 1H),
4.67 (s, 2H), 4.12 (q, J = 7.0 Hz, 2H), 3.42–3.36 (m, 1H), 3.35 (s, 3H),
2.37–0.80 (m), 1.00 (s, 3H), 0.60 (s, 3H); 13C NMR (CDCl3) δ 173.8,
140.7, 121.5, 94.6, 76.8, 60.0, 55.5, 55.1, 50.3, 46.7, 41.9, 39.5, 37.2,
37.1, 36.7, 35.2, 31.9, 31.8, 28.9, 28.1, 24.5, 20.7, 19.3, 14.2, 12.3.
ent-steroid 10. To a solution of the ent-steroid 7 (202 mg,
0.5 mmol) in tetrahydrofuran (THF) (10 ml), lithium diisopropylamide (0.75 ml, 2.0 M in THF, 1.5 mmol) and HMPA
(0.29 ml, 1.65 mmol) were added at –78◦ C. After 1 h, 1-bromo-4methylpentane (0.44 ml, 3 mmol) was added. After addition,
the reaction was warmed to room temperature for 16 h.
Aqueous NH4Cl was added and extracted with EtOAc
(100 ml × 2), and the combined extracts were dried over
anhydrous Na2SO4. The solvent was removed under reduced
pressure, and the residue was purified by flash column
chromatography (silica gel eluted with 20% EtOAc in hexanes) to give ent-steroid 10 (236 mg, 97%): 1H NMR (400 MHz,
CDCl3) δ 5.34–5.33 (m, 1H), 4.67 (s, 2H), 4.13–4.08 (q, J = 7.4 Hz,
2H), 3.41–3.37 (m, 1H), 3.35 (s, 3H), 2.35–0.79 (m), 0.98 (s, 3H), 0.70
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 176.2, 140.7, 121.5, 94.6, 76.9,
59.6, 56.0, 55.1, 52.6, 50.1, 47.4, 41.9, 39.5, 38.8, 37.5, 37.2, 36.7, 32.2,
31.8, 31.7, 28.9, 27.8, 27.0, 25.0, 23.8, 22.7, 22.3, 20.8, 19.3, 14.2, 12.0.
ent-steroid 11. To a solution of ent-steroid 10 (236 mg,
0.5 mmol) in diethyl ether (20 ml), LiAlH4 (2.0 M in diethyl
ether, 4.0 ml, 8.0 mmol) was added at room temperature. After
2 h, water (0.32 ml), 10% of NaOH (0.64 ml), and water (0.96 ml)
were slowly added sequentially. After stirring for 30 min, the
mixture was filtered through Celite and washed with CH2Cl2
(100 ml). The solvent was removed under reduced pressure

and the residue was purified by flash column chromatography (silica gel eluted with 25% EtOAc in hexanes) to give entsteroid 11 (212 mg, 98%): 1H NMR (400 MHz, CDCl3) δ 5.34–5.33
(m, 1H), 4.66 (s, 2H), 3.71–3.61 (m, 2H), 3.44–3.36 (m, 1H), 3.34 (s,
3H), 2.35–0.88 (m), 0.99 (s, 3H), 0.68 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 140.6, 121.6, 94.6, 76.7, 62.5, 56.6, 55.1, 50.3, 50.1, 42.3,
42.0, 39.5, 39.1, 37.2, 36.6, 31.8, 29.5, 28.8, 27.9, 27.5, 24.1, 24.0, 22.7,
22.5, 21.0, 19.3, 12.1.
ent-steroid 12. To a solution of ent-steroid 11 (212 mg,
0.48 mmol) in CH2Cl2 (10 ml), mesyl chloride (1 mmol, 0.08 ml)
and Et3N (0.28 ml, 2 mmol) were added at 0◦ C. After 1 h,
aqueous NH4Cl was added and the product was extracted into
CH2Cl2 (100 ml × 2). The combined extracts were dried over
anhydrous Na2SO4 and filtered and the solvents removed.
The residue was purified by flash column chromatography
(silica gel eluted with 10% EtOAc in hexanes) to give ent-steroid 12 (241 mg, 97%): 1H NMR (400 MHz, CDCl3) δ 5.33–5.32
(m, 1H), 4.66 (s, 2H), 4.36–4.32 (m, 1H), 4.18–4.09 (m, 1H),
3.42–3.37 (m, 1H), 3.34 (s, 3H), 2.97 (s, 3H), 2.34–0.89 (m), 0.98 (s,
3H), 0.69 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 140.6, 121.4, 94.6,
76.8, 70.0, 56.4, 55.1, 50.0, 49.9, 42.0, 39.7, 39.4, 39.2, 39.0, 37.2, 37.1,
36.6, 31.7, 31.6, 29.4, 28.8, 27.7, 27.4, 24.0, 23.4, 22.6, 22.4, 20.9, 19.3,
12.1.
ent-steroid 13. To a solution of ent-steroid 12 (241 mg,
0.46 mmol) in diethyl ether (30 ml), LiAlH4 (2.0 M in diethyl
ether, 4.0 ml, 8.0 mmol) was added at room temperature. After
2 h, water (0.32 ml), 10% of NaOH (0.64 ml), and water (0.96 ml)
were slowly added sequentially. After stirring for 30 min, the
mixture was filtered through Celite and washed with CH2Cl2
(100 ml). The solvent was removed under reduced pressure
and the residue was purified by flash column chromatography (silica gel eluted with 10% EtOAc in hexanes) to give entsteroid 13 (188 mg, 95%): 1H NMR (400 MHz, CDCl3) δ 5.35–5.34
(m, 1H), 4.68 (s, 2H), 3.46–3.38 (m, 1H), 3.36 (s, 3H), 2.37–0.86 (m),
1.01 (s, 3H), 0.68 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 140.7, 121.7,
94.6, 76.9, 56.7, 56.1, 55.1, 50.1, 42.3, 39.8, 39.5, 39.4, 37.2, 36.7, 36.2,
35.8, 31.9, 31.8, 28.9, 28.2, 28.0, 24.3, 23.8, 22.8, 22.5, 21.0, 19.3, 18.7,
11.8.
ent-steroid 14 (ent-cholesterol). To a solution of ent-steroid 13
(188 mg, 0.44 mmol) in THF (20 ml), 6 N HCl (10 ml) was added
at room temperature. After 4 h, the product was extracted
into CH2Cl2 (100 ml × 2) and the combined extracts were
washed with aqueous NaHCO3 (50 ml × 2), dried over anhydrous Na2SO4, and filtered. The solvent was removed under
reduced pressure, and the residue was purified by flash column chromatography (silica gel eluted with 20% EtOAc in
hexanes) to give ent-steroid 14 (165 mg, 98%); 1H NMR
(400 MHz, CDCl3) δ 5.36–5.35 (m, 1H), 3.57–3.49 (m, 1H),
2.33–0.86 (m), 1.01 (s, 3H), 0.68 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 140.7, 121.7, 71.8, 56.7, 56.1, 50.1, 42.3, 42.2, 39.8, 39.5,
37.2, 36.5, 36.2, 35.8, 31.9(2C), 31.6, 28.2, 28.0, 24.3, 23.8, 22.8, 22.6,
21.1, 19.4, 18.7, 11.8.
ent-steroid 15 (ent-4β-HC). A procedure previously reported to convert cholesterol to 4β-HC was used (68) to
convert ent-cholesterol 14 into ent-4β-HC 15.
To a solution of ent-cholesterol 14 (29 mg, 0.0747 mmol) in
dioxane (5 ml) and water (2 drops), SeO2 (17 mg, 0.15 mmol)
was added at room temperature. The mixture was heated to
90◦ C for 16 h. After cooling to room temperature, the solvent
was removed under reduced pressure. The residue was purified by flash column chromatography (silica gel eluted with
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30% EtOAc in hexanes) to give ent-4β-HC 15 (17 mg, 58%): mp
169–171◦ C; [α]D20 +41.7 (c = 0.12, CHCl3); 1H NMR (400 MHz,
CDCl3) δ 5.69–5.68 (m, 1H), 4.15–4.14 (m, 1H), 3.58–3.55 (m, 1H),
2.20–0.78 (m), 1.19 (s, 3H), 0.69 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 142.7, 128.8, 77.3, 72.5, 56.9, 56.1, 50.2, 42.3, 39.7, 39.5,
36.9, 36.2, 36.0, 35.8, 32.1, 31.8, 28.2, 28.0, 25.4, 24.2, 23.8, 22.8, 22.5,
21.0, 20.5, 18.7, 11.8; IR (film, cm−1) 3406, 1455, 1366, 1072.
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